Skip to content

Study · Case report or series · 1998

4 results

Role of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty. Report of six cases.

Stewart L, Steinbok P, Daaboul J

Journal of neurosurgery1 Feb 1998Cited by 28 (Europe PMC)

PMID9452248 (opens in a new tab)DOI10.3171/jns.1998.88.2.0340 (opens in a new tab)PepBankPUB-09452248
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In children with hypothalamic hamartomas, no side effects were noted during Decapeptyl treatment.

    In plain wordsIn children with hypothalamic hamartomas, no side effects were reported with Decapeptyl.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableSide effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No side effects were noted with decapeptyl treatment,
    2 context sentences
    Summary · context
    The authors report the long-term results of total resection of HHs in two children with central precocious puberty and compare it with medical management in four children.
    Summary · context
    Four children were treated solely with GnRH agonists and have received follow-up care for 2.3, 6, 9, and 9 years, respectively.

Studies that did not test the peptide alone3

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    In children with hypothalamic hamartomas, pooled GnRH agonist treatment produced complete regression of endocrinological abnormalities.

    In plain wordsIn children with hypothalamic hamartomas, pooled GnRH agonist treatment reversed endocrine abnormalities.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseEndocrinological abnormalities
    Study

    n = 4

    Outcome group
    Linear growth · Endocrine and hormones

    Source sentences

    Summary
    These patients have had a complete regression of endocrinological abnormalities, including a normalization of growth velocity and reduction in the rate of skeletal maturation.
    2 context sentences
    Summary · context
    The authors report the long-term results of total resection of HHs in two children with central precocious puberty and compare it with medical management in four children.
    Summary · context
    Four children were treated solely with GnRH agonists and have received follow-up care for 2.3, 6, 9, and 9 years, respectively.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    In children with hypothalamic hamartomas, pooled GnRH agonist treatment normalized growth velocity.

    In plain wordsIn children with hypothalamic hamartomas, pooled GnRH agonist treatment normalized growth speed.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseGrowth velocity normalization
    Study

    n = 4

    Outcome group
    Linear growth · Endocrine and hormones

    Source sentences

    Summary
    These patients have had a complete regression of endocrinological abnormalities, including a normalization of growth velocity and reduction in the rate of skeletal maturation.
    2 context sentences
    Summary · context
    The authors report the long-term results of total resection of HHs in two children with central precocious puberty and compare it with medical management in four children.
    Summary · context
    Four children were treated solely with GnRH agonists and have received follow-up care for 2.3, 6, 9, and 9 years, respectively.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    In children with hypothalamic hamartomas, pooled GnRH agonist treatment reduced skeletal maturation rate.

    In plain wordsIn children with hypothalamic hamartomas, pooled GnRH agonist treatment slowed bone maturation.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseSkeletal maturation rate
    Study

    n = 4

    Outcome group
    Linear growth · Endocrine and hormones

    Source sentences

    Summary
    These patients have had a complete regression of endocrinological abnormalities, including a normalization of growth velocity and reduction in the rate of skeletal maturation.
    2 context sentences
    Summary · context
    The authors report the long-term results of total resection of HHs in two children with central precocious puberty and compare it with medical management in four children.
    Summary · context
    Four children were treated solely with GnRH agonists and have received follow-up care for 2.3, 6, 9, and 9 years, respectively.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.